What is the mechanism of action of margetuximab? In what ways does it exert its therapeutic effect?

Margetuximab (Margetuximab) is a monoclonal antibody targeting HER2 (human epidermal growth factor receptor 2)-positive cancer. It is mainly used to treat HER2-positive breast cancer. Compared with traditional anti-HER2 therapeutic drugs (such as trastuzumab), margetuximab has been optimized in molecular structure to enhance its anti-cancer effect, especially in enhancing the anti-tumor ability of the immune system.

The main mechanisms of action includeHER2 receptor blockade and enhancement of antibody-dependent cell-mediated cytotoxicity (ADCC). Margetuximab inhibits the growth and proliferation of tumor cells by binding to the HER2 receptor and blocking its signaling pathway. At the same time, it can effectively block the downstream signaling of HER2 receptors, reduce the growth power of cancer cells, and inhibit their ability to spread and invade.

Compared with trastuzumab, margetuximab has been improved in optimizing the Fc segment of the antibody, allowing it to activate the immune system more effectively, specifically enhancing the ADCC effect. This mechanism allows immune cells (such as natural killer cells) to more effectively identify and eliminate HER2-positive cancer cells, thereby improving the therapeutic effect. Studies have shown that margituximab may have an advantage in patients with specific mutations in the RIIIa gene, meaning some patient groups may get better results from the drug.

In general, margituximab exerts anti-tumor effects by blocking HER2 signals and enhancing the killing ability of the immune system, and shows good prospects in the treatment of HER2 positive breast cancer. Especially in patients who are resistant to or have poor efficacy of trastuzumab, margetuximab can be used as a new treatment option to provide a more effective treatment option for patients with HER2 positive breast cancer.

Reference materials:https://www.margenza.com/